Physician profile
Jenny M Daubert
NPI 1548676778
$7,088.36
in general payments reported to CMS, 2019-2025
31 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,252 · 2022: $1,444 · 2023: $1,790 · 2024: $2,051 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,302 · Education: $90.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,302.06 |
| Education | $90.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,866.46 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,239.14 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $581.69 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $361.59 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $359.55 | 2022-2025 | |
| Qol Medical, LLC | $354.67 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $277.22 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $258.21 | 2022-2024 | Dupixent |
| Daiichi Sankyo INC. | $249.70 | 2021-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $233.70 | 2021-2024 | Linzess |
| Ardelyx, INC. | $194.64 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $179.23 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $139.35 | 2021-2024 | Dificid |
| Celgene Corporation | $109.44 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $78.33 | 2024-2025 | Zenpep |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $71.88 | 2021 | |
| Madrigal Pharmaceuticals | $63.62 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $55.96 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $52.04 | 2024-2025 | Vegzelma, Zymfentra |
| Fresenius Kabi USA, LLC | $48.11 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $41.22 | 2023-2024 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $37.12 | 2022 | |
| Amgen INC. | $35.20 | 2021-2023 | Amjevita |
| Evoke Pharma, INC. | $30.23 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $28.22 | 2022-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $27.02 | 2022-2023 | Ocaliva |
| Alfasigma USA, INC. | $22.65 | 2021 | |
| Lilly USA, LLC | $20.03 | 2024 | Omvoh |
| Sandoz INC. | $18.45 | 2025 | Pyzchiva |
| Redhill Biopharma INC. | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Daubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.